MedReleaf Continues to Lead on Scientific Research: Landmark, Peer-Reviewed Study Shows Medical Cannabis Dramatically Improves Lives of Veterans with PTSD

MedReleaf, Canada's premium licensed producer of medical cannabis, today announced the findings from a landmark study on the effectiveness of medical cannabis on military veterans diagnosed with PTSD. The study found treatment with medical cannabis improved aggregate patient reported outcomes by 50-60% with a 77% decrease in suicidal thoughts as well as a 50% reduction in the consumption of related medications.  

The study, being presented today in Vancouver at the 7th Annual Military and Veteran Health Research Forum, was conducted by Dr. Paul Smith, MD, using several of MedReleaf's proprietary strains of medical cannabis including AviDekel, Luminarium and Midnight.

From baseline to follow up, the study revealed a number of key insights on patient outcomes including:

  • Aggregate score of both PTSD symptoms and social impacts improved by 59%
  • Drug and alcohol overuse was reduced by 82%
  • Marital and relationship harmony improved 65% and
  • Severity of pain experienced by patients decreased 48%
  • ...
e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.